A yak gene that defies thin air might also fix damaged nerves

Yaks do not get altitude sickness. Neither do Tibetan antelopes. Both species thrive on the Tibetan Plateau, where the average elevation sits at roughly 14,700 feet and oxygen levels would leave most mammals gasping. Scientists have long suspected a gene called Retsat plays a role in that resilience - but the latest findings suggest its benefits extend far beyond breathing.

From plateau to petri dish

A team led by Liang Zhang at Songjiang Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, set out to test whether the high-altitude Retsat mutation could protect the myelin sheath - the insulating layer that wraps nerve fibers and keeps electrical signals moving efficiently through the brain and spinal cord. When myelin breaks down, the consequences range from cerebral paralysis in newborns to multiple sclerosis (MS) in adults to vascular dementia in the elderly.

The researchers exposed newborn mice to low-oxygen conditions equivalent to elevations above 13,000 feet for about a week. Mice carrying the Retsat mutation performed significantly better on tests of learning, memory, and social behavior than those with the standard version of the gene. Brain imaging confirmed the reason: these mice had notably more myelin surrounding their nerve fibers.

The MS connection

That was promising, but Zhang's team wanted to push further. They tested whether the mutation could actually repair myelin damage - the kind of destruction seen in MS, where the immune system attacks the sheath directly.

It could. In mice carrying the high-altitude variant, the myelin sheath regenerated faster and more completely after injury. The damaged sites also contained more mature oligodendrocytes, the specialized cells responsible for producing myelin in the first place. The mutation was not merely protective. It was restorative.

A vitamin A derivative does the heavy lifting

Digging into the mechanism, the team found that mice with the Retsat mutation produced higher levels of a molecule called ATDR (all-trans-dihydroretinoic acid), a metabolite derived from vitamin A. The mutation appeared to boost the enzymatic activity that converts vitamin A into ATDR, which in turn promoted both the production and maturation of oligodendrocytes.

Here is where the finding gets particularly interesting: ATDR is not a foreign compound. Every human body already makes it. The question is whether most people produce enough of it to drive meaningful myelin repair.

When the researchers administered ATDR directly to mice with an MS-like disease, the animals showed decreased disease severity and improved motor function. Current MS treatments primarily work by suppressing the immune system - a necessary but blunt approach that does nothing to rebuild what has already been lost. ATDR, by contrast, appears to operate on the repair side of the equation.

What this does not tell us yet

This is mouse work, and the leap from rodent models to human therapy is long and littered with failures. The study used engineered mice carrying a specific genetic variant, which is not directly analogous to delivering ATDR as a drug to a person with MS. Dosing, timing, delivery method, and potential side effects in humans remain entirely unknown.

The sample sizes were also relatively small, and the MS-like model in mice - called experimental autoimmune encephalomyelitis - does not perfectly recapitulate human MS, which is more heterogeneous in its progression and pathology.

Still, the idea of exploiting a naturally occurring metabolite rather than engineering an entirely synthetic drug has obvious appeal. It sidesteps some toxicity concerns and could, in theory, complement existing immunosuppressive therapies rather than replace them.

Evolution as a drug discovery engine

Zhang frames the work as part of a broader philosophy. Natural selection has been running experiments for millions of years, and the genetic toolkit that emerged from high-altitude adaptation represents a largely untapped pharmacological resource.

The Retsat variant is one example. The broader question is how many other adaptive mutations - in humans, in livestock, in wildlife - encode molecular solutions to diseases we currently struggle to treat. Evolutionary biology and translational medicine rarely occupy the same conversation. This study suggests they probably should.